Effects of Intravenous (IV) Omadacycline on Gut Microbiome - Trial NCT05515562
Access comprehensive clinical trial information for NCT05515562 through Pure Global AI's free database. This Phase 4 trial is sponsored by Wake Forest University Health Sciences and is currently Not yet recruiting. The study focuses on Microbial Colonization. Target enrollment is 8 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Wake Forest University Health Sciences
Timeline & Enrollment
Phase 4
Dec 01, 2022
Dec 01, 2023
Primary Outcome
Change in gut microbiota concentrations
Summary
Given the clinical need to improve upon current antibiotic regimens for the treatment of C.
 difficile infection with a particular focus on the impact of therapies on gut microbiome,
 this study proposes to characterize the impact of Intravenous (IV) omadacycline on gut
 microbiome of healthy volunteers.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05515562
Non-Device Trial